Prenatal exposure to antidepressants: How safe are they?

American Journal of Psychiatry

Volumn 169, Issue 11, 2012, Pages 1130-1132

  Steiner, Meir ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b Women's Health Concerns Clinic   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADAPTATION SYNDROME; APGAR SCORE; BEHAVIOR DISORDER; BIRTH DEFECT; BIRTH WEIGHT; COGNITIVE DEFECT; DISEASE ASSOCIATION; EDITORIAL; GESTATIONAL AGE; HIGH RISK PREGNANCY; HUMAN; LANGUAGE DISABILITY; MENTAL DISEASE; NEWBORN DISEASE; PRENATAL EXPOSURE; PRIORITY JOURNAL; PUERPERAL DEPRESSION;

EID: 84868538928     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2012.12081126     Document Type: Editorial

References (18)

1. Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood C: The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009; 31:403-413
2. National Institute for Health and Clinical Excellence (NICE): Antenatal and Postnatal Mental Health: The NICE Guideline on Clinical Management and Service Guidance. Leicester, UK, British Psychological Society, 2007
3. Scottish Intercollegiate Guidelines Network (SIGN): Management of Perinatal Mood Disorders: A National Clinical Guideline. Edinburgh, SIGN, 2012
4. Black Dog Institute: Safety of Antidepressants in Pregnancy and Breastfeeding. Randwick, Australia, Black Dog Institute, 2012
5. Centers for Disease Control and Prevention (CDC): Update on overall prevalence of major birth defects- Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep 2008; 57:1-5
6. Bérard A, Ramos E, Rey E, Blais L, St-André M, Oraichi D: First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80:18-27
7. Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jong-van den Berg LT: First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010; 88:94-100
8. El Marroun H, Jaddoe VW, Hudziak JJ, Roza SJ, Steegers EA, Hofman A, Verhulst FC, White TJ, Stricker BH, Tiemeier H: Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry 2012; 69:706-714
9. Occhiogrosso M, Omran SS, Altemus M: Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies. Am J Psychiatry 2012; 169:134-140
10. Spinelli M: Antidepressant treatment during pregnancy (commentary). Am J Psychiatry 2012; 169:121-124
11. Diav-Citrin O, Ornoy A: Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat? Obstet Gynecol Int 2012; 2012:698947
12. Ross LE, Mamisashvili L, VonderPorten EH, Roerecke M, Rehm J, Dennis C-L, Koren G, Steiner M, Mousmanis P, Cheung A, Grigoriadis S: Effects of prenatal antidepressant treatment on pregnancy and delivery outcomes: a systematic review and meta-analysis. Arch Gen Psychiatry (in press)
13. Pedersen LH, Henriksen TB, Olsen J: Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010; 125:e600-e608
14. Nordeng H, van Gelder MM, Spigset O, Koren G, Einarson A, Eberhard-Gran M: Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2012; 32:186-194
15. Sandman CA, Davis EP, Buss C, Glynn LM: Exposure to prenatal psychobiological stress exerts programming influences on the mother and her fetus. Neuroendocrinology 2012; 95:8-21
16. Buss C, Davis EP, Hobel CJ, Sandman CA: Maternal pregnancy-specific anxiety is associated with child executive function at 6-9 years age. Stress 2011; 14:665-676
17. Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, Feldman B: Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry 2012; 169:1165-1174
18. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, Koren G: Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159:1889-1895 (Pubitemid 35283255)